RA Capital Management and Polaris Partners led a $160m Series B round for Freenome, a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. They were joined by other new investors including Novartis, T Rowe Price Associates, FMR, Farallon Capital Management, Kaiser Permanente Ventures, Roche Venture Fund, Andreessen Horowitz, Data Collective, EcoR1 Capital, Rock Springs Capital, Perceptive Advisors, Cormorant Asset Management, Section 32, Janus Henderson Investors, Soleus Capital Management, Sands Capital Ventures, Bain Capital Life Sciences, BrightEdge, Catalio Capital Management and Colorectal Cancer Alliance. "We are fortunate to have an experienced and proven group of biotech and healthcare investors who share our mission of making early detection of cancer a routine part of patient care. In addition, we are excited to welcome several strategic investors who are committed to our mission. Each brings insight, expertise, and partnership opportunities to accelerate our path to positively impacting patient care," Gabe Otte, Freenome Chief Executive Officer.